MashupMD

Mashup Score: 1

Cardiovascular Medical Events in Patients with CLL, SLL Treated With Acalabrutinib or Zanubrutinib | Blood Cancers Today - 10 hour(s) ago

Fewer patients in the acalabrutinib group experienced treatment-emergent cardiovascular medical events after BTKi initiation compared with those in the zanubrutinib group.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  ❤️ A study presented at #ASH24 by Jing-Zhou Hou, MD, PhD (@UPMC) outlined the treatment-emergent cardiovascular medical events among patients with #CLL or #SLL treated with acalabrutinib or zanubrutinib in the community oncology setting. 📚 Read here: https://t.co/7tFXAzOUzW https://t.co/Plk2928i1V